|Bid||134.07 x 100|
|Ask||134.16 x 200|
|Day's Range||129.61 - 134.20|
|52 Week Range||75.52 - 153.15|
|PE Ratio (TTM)||-237.39|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Q1 2017 Incyte Corp Earnings Call
Shares of Seattle Genetics (SGEN) are moving lower today, falling more than 9% after the drug maker’s experimental lymphoma drug failed to impress. The data from the late-stage study testing Adcetris, co-developed with Japan's Takeda Pharmaceutical, helped blood cancer patients live longer without worsening their conditions, meeting its endpoint. Altogether, lots of uncertainty whether these data could support a robust commercial adoption.
Biotech shares have surged during the week of June 19.